re: Ann: Prima Files US Shelf Registration St... BoilerYou're...

re: Ann: Prima Files US Shelf Registration St... Boiler
You're correct in saying that CAN003 is not a double blind trial and there is no placebo arm. That is what CAN004 is for, as well as being statistically powered with 800 patients, so it can eventually be submitted for FDA approval.

There was never any doubt that additional funds will be needed to bring CAN004 to completion. The only question is when, how and how much. Best guess would be about $50-60 million.

When? Well if CAN003 does not demonstrate a sufficient median PFS benefit, the point will be moot. If it does, a whole range of funding options become available. These include:

1/ A further SPP, presumably at a much higher level than the last.

2/ Partnering with a pharma on JV or marketing agreement with an upfront payment that funds the trial to completion, or

3/ A US Cap Raising, utilising the facility announced today. That's clearly what this was for, planning ahead on the presumption Cvac proves efficacious. It means the facility is in place, a bit like a line of credit.